| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.025 | 0.9 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.016 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.9 |
| mRNA | Vinblastine | GDSC1000 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |